Skip to main content
Top navigation
  • Sustainability reports
  • Focus area: Increase resource efficiency
  • Governance
  • Please fill out this field

Main navigation

    • Our offering
        • Solids & others
            • Manufacturing
                • Solids
                • Semi-solids
                • Liquids
                • Pharmaceutical packaging
                • Controlled drugs
                • High Potent
        • Sterile delivery
            • Manufacturing
                • Sterile vial filling
                • PFS and cartridges
                • Lyophilisation
                • Blow-fill-seal
                • Ampoules
            • Specialised services
                • Ophthalmics
                • Beta-lactams
                • Vaccine manufacturing
        • Advanced Bio
            • Modalities & services
                • xRNA therapies
                • Virus & viral vectors
                • Microbial & live biotherapeutic products
                • Recombinant proteins
            • Continuous manufacturing
            • Innovations & collaborations
        • Additional services
            • ReciPredict
            • Analytical services
            • Regulatory
            • Parenteral drug development
            • New product introduction
                • Technology Transfer
                • Product development
    • Resources
    • About us
        • About us
            • Our leadership
            • Why partner with us
            • Locations
        • Sustainability
            • Sustainability reports
            • Sustainability strategy
            • Net Zero commitment
            • Governance
        • News & Events
            • Press releases
            • Events
    • Careers
        • Careers
            • Who we are
            • Working with us
            • What you can do
            • Job search
    • Contact
Linkedin
Contact
Please fill out this field
No banner Image

  • Home
  • Facebook
  • Linkedin
  • Twitter
  • Email
December 11 2023
ReciBioPharm partners with Acuitas Therapeutics to provide rapid technology transfers and CGMP manufacture of Acuitas' LNP formulations
November 21 2023
Recipharm annonce cesser ses activités mi-2025 sur son site de Monts, France, et va déployer ses efforts pour la recherche d'un repreneur
June 05 2023
Statement from Arranta Bio on settlement of Thermo Fisher litigation
May 04 2023
Recipharm makes senior appointment to head up biologics business unit, ReciBioPharm
May 02 2023
FDA approves the manufacture of new microbiome-based therapeutic VOWST™ at Recipharm site
April 28 2023
Arranta Bio, a Recipharm company, signs contract with MIT to develop rapid manufacturing of mRNA therapeutics
April 04 2023
Recipharm bolsters senior leadership team with appointment of Joaquim Mascaro as Chief Financial Officer
March 09 2023
Recipharm's Arranta Bio expands RNA process development capacity by 50 per cent to meet increased customer demand
December 05 2022
Recipharm announces extension of commercial manufacturing to support RedHill Biopharma's Talicia® to 2026
October 25 2022
Recipharm bolsters blow-fill-seal capabilities with Lab+

Pagination

  • First page
  • Previous page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Page 7
  • Page 8
  • Next page
  • Last page
Subscribe to

Footer Webfrom

contact form

Let’s discuss your 
next project

Share your details and start your journey with our global CDMO team.

Stay updated
https://se.linkedin.com/company/recipharm https://www.youtube.com/channel/UCr-bw7pCCkYZfeImOwTfNRg
Footer
  • Privacy policy
  • Cookies
  • Website terms
  • Sitemap
  • Cookie settings
  • Terms & conditions
  • Code of Conduct
© 2026

Recipharm AB. All rights reserved. RECIPHARM® is a registered trademark owned by Recipharm AB.

Delivered by Investisdigital [iDX]